-Financing co-led by Cobro Ventures and Taiwania Capital Management Corporation; Michael Huang, Managing Partner at Taiwania joins the Regenacy Board of Directors- WALTHAM, Mass., March 25, 2020-- Regenacy Pharmaceuticals, a clinical-stage biopharmaceutical company developing breakthrough treatments for diabetic and other peripheral neuropathies, today announced the closing of a $30 million Series A financing. The financing was co-led by Cobro Ventures and Taiwania Capital Management Corporation, with participation from 3E Bioventures Capital, Yonjin Capital, VIVA Biotech Holdings, TA YA VENTURE HOLDINGS LIMITED, and other undisclosed private investors.
